Toxicity profile of the new compound XC221GI from pre-clinical studies

Abstract

The major feature of COVID-19 is intensive virus-induced inflammation in vital body organs and spatiotemporal dysregulation of pro- and anti-inflammatory cytokines and chemokines synthesis. All this leads to unpredicted clinical progression and high risk of "cytokine storm" development. The "cytokine storm" is the pathogenetic basis for further development of life-threatening complications. Thus, there is a huge need to select effective and safe approaches that allow to control virus-induced inflammation as a part of preventive anti-inflammatory therapy.

This article presents toxicological characteristics of the original low-molecular compound XC221GI (1-[2-(1-methylimidazole-4-yl)-ethyl]perhydroazin-2,6-dione) from pre-clinical studies.

The obtained results demonstrate that the XC221GI does not have any toxic effect in repeated long-term administration. The compound was well tolerated by all animals. The no-observed-adverse-effect level (NOAEL) was 30 mg/kg per day for dogs and 450 mg/kg per day for rats. There were no effects of XC221GI on blood count, hematopoiesis and hemostasis. As well as no cytotoxic, mutagenic, genotoxic, carcinogenic properties or anaphylactogenic and immunotoxic activity were revealed for XC221GI. All known data enable to classify XC221GI as a low toxic compound and consider its safety profile as reasonably favorable.

Keywords

COVID-19 / preventive anti-inflammatory therapy / ХС221GI / toxicology

References

[1] Ruelens M, Wouters J. COVID-19 and the trials and tribulations of global health governance. Bulletin of International Organizations. 2021;16(2):70–98. (In Russ). doi: 10.37690/1811-0193-2020-4-24-33

[2] Рюленс М., Ваутерс Я. COVID-19: испытания и потрясения для глобального управления в сфере здравоохранения // Вестник международных организаций. 2021. Т. 16, № 2. С. 70–98. doi: 10.17323/1996-7845-2021-02-05

[3] Tang L, Yin Z, Hu Y, Mei H. Controlling cytokine storm is vital in COVID-19. Front Immunol. 2020;11:570993. doi: 10.3389/fimmu.2020.570993

[4] Tang L., Yin Z., Hu Y., Mei H. Controlling cytokine storm is vital in COVID-19 // Front Immunol. 2020. Vol. 11. Р. 570993. doi: 10.3389/fimmu.2020.570993

[5] Pavlikova EP, Agapov MA, Malakhov PS, et al. Mediastinal emphysema as a specific complication of COVID-19 (case report). General Reanimatology. 2021;17(2):4–15. (In Russ). doi: 10.15360/1813-9779-2021-2-4-15

[6] Павликова Е.П., Агапов М.А., Малахов П.С., и др. Эмфизема средостения — специфическое осложнение COVID-19 (клиническое наблюдение) // Общая реаниматология. 2021. Т. 17, № 2. С. 4–15. doi: 10.15360/1813-9779-2021-2-4-15

[7] Pasrija R, Naime M. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. Int Immunopharm. 2021;90:107225. doi: 10.1016/j.intimp.2020.107225

[8] Pasrija R., Naime M. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease // Int Immunopharm. 2021. Vol. 90. Р. 107225. doi: 10.1016/j.intimp.2020.107225

[9] Griffin DO, Brennan-Rieder D, Ngo B, et al. The importance of understanding the stages of COVID-19 in treatment and trials. AIDS Rev. 2021;23(1):40–47. doi: 10.24875/AIDSRev.200001261

[10] Griffin D.O., Brennan-Rieder D., Ngo B., et al. The Importance of understanding the stages of COVID-19 in treatment and trials // AIDS Rev. 2021. Vol. 23, N 1. Р. 40–47. doi: 10.24875/AIDSRev.200001261

[11] National Research Council (US) Institute for Laboratory Animal Research. Guide for the care and use of laboratory animals. Washington (DC): National Academies Press (US); 1996. doi: 10.17226/5140

[12] National Research Council (US) Institute for Laboratory Animal Research. Guide for the care and use of laboratory animals. Washington (DC): National Academies Press (US), 1996. doi: 10.17226/5140

[13] Buresh Ya, Bureshova O, Houston DP. Methods and basic experiments on the study of the brain and behavior. Transl. from English by E.N. Pictortseva; ed. by A.S. Batuev. Moscow: Vysshaya shkola; 1991. 398 p. (In Russ).

[14] Буреш Я., Бурешова О., Хьюстон Д.П. Методики и основные эксперименты по изучению мозга и поведения / пер. с англ. Е.Н. Живописцевой; под ред. А.С. Батуева. Москва: Высшая школа, 1991. 398 с.

[15] Bunyatyan ND, Vasiliev AN, Verstakova OL, et al. Guidelines for conducting preclinical studies of medicines. Ed. by A.N. Mironov. Moscow: Grif i K; 2012. 944 p. (In Russ).

[16] Бунятян Н.Д., Васильев А.Н., Верстакова О.Л., и др. Руководство по проведению доклинических исследований лекарственных средств / под ред. А.Н. Миронова. Москва: Гриф и К, 2012. 944 с.

[17] Van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39–50. doi: 10.1038/s41591-021-01643-9

[18] Van de Veerdonk F.L., Giamarellos-Bourboulis E., Pickkers P., et al. A guide to immunotherapy for COVID-19 // Nat Med. 2022. Vol. 28, N 1. Р. 39–50. doi: 10.1038/s41591-021-01643-9

[19] Philippova AV, Kolbin AS, Verbitskaya EV, et al. Safety issues of monoclonal antibodies used in rheumatology. Good Clinical Practice. 2019;(3):44–52. (In Russ.) doi: 10.24411/2588-0519-2019-10082

[20] Филиппова А.В., Колбин А.С., Вербицкая Е.В., и др. Вопросы безопасности лекарственных средств моноклональных антител, применяемых в ревматологии // Качественная клиническая практика. 2019. № 3. С. 44–52. doi: 10.24411/2588-0519-2019-10082.

[21] Kolbin AS, Kharchev AV. Safety of biological preparations and small molecules. Are there any differences? Pediatric Pharmacology. 2013;10(3):17–25. (In Russ).

[22] Колбин А.С., Харчев А.В. Безопасность биопрепаратов и малых молекул. Существуют ли различия? // Педиатрическая фармакология. 2013. Т. 10, № 3. С. 17–25.

[23] Giezen TJ, Mantel-Teeuwisse AK, Leufkens HG. Pharmacovigilance of biopharmaceuticals: challenges remain. Drug Saf. 2009;32(10): 811–817. doi: 10.2165/11316550-000000000-00000

[24] Giezen T.J., Mantel-Teeuwisse A.K., Leufkens H.G. Pharmacovigilance of biopharmaceuticals: challenges remain // Drug Saf. 2009. Vol. 32, N 10. Р. 811–817. doi: 10.2165/11316550-000000000-00000

[25] Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914–1920. doi: 10.1136/ard.2011.151043

[26] Strangfeld A., Eveslage M., Schneider M., et al. Treatment benefit or survival of the fi ttest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? // Ann Rheum Dis. 2011. Vol. 70, N 11. Р. 1914–20. doi: 10.1136/ard.2011.151043

Funding

ООО «Фарминтепрайзес»Pharmenterprises LLC

АО «Валента Фарм»JSC Valenta Pharm

RIGHTS & PERMISSIONS

Eco-vector